Orvida Pharma (Formerly Kamari)

Mariposa Therapeutics

This biotechnology company develops a topical small-molecule therapy for patients with the rare genetic skin condition epidermolysis bullosa simplex.

Escient Pharmaceuticals

This company develops small molecule therapeutics for patients with neurosensory-inflammatory disorders, such as chronic urticaria, atopic dermatitis and cholestatic pruritus.

Arcutis Biotherapeutics

This biopharmaceutical company develops and commercialises topical treatments for patients with chronic inflammatory skin diseases such as psoriasis, eczema, and seborrhoeic dermatitis.

Krystal Biotech

This biotechnology company develops and commercialises redosable gene therapies for patients with rare genetic diseases, including dystrophic epidermolysis bullosa.

Brickell Bio

This pharmaceutical company develops prescription therapeutics for patients with autoimmune, inflammatory and debilitating skin diseases.

Evommune

This biotechnology company develops medicinal therapies to treat patients suffering from chronic inflammatory and immune-mediated diseases.

Curzion Pharmaceuticals

This biopharmaceutical company develops oral small molecule therapies to treat patients with rare fibrotic conditions like diffuse cutaneous systemic sclerosis.

BioMendics

BioMendics develops liquid crystal small molecule therapeutics for patients suffering from rare genetic dermatologic disorders such as epidermolysis bullosa simplex.